- Home
- BSBK vs WHWK Comparison
BSBK vs WHWK Comparison
Compare BSBK & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSBK | WHWK |
|---|---|---|
| Founded | 1893 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.1M | 95.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BSBK | WHWK |
|---|---|---|
| Price | $8.16 | $2.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.7K | ★ 182.6K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $15,989,970.00 | $14,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $216.81 | ★ N/A |
| Revenue Growth | ★ 31.80 | N/A |
| 52 Week Low | $6.59 | $1.39 |
| 52 Week High | $9.50 | $3.81 |
Technical Indicators
Market Signals| Indicator | BSBK | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 35.03 | 61.91 |
| Support Level | $8.14 | $2.10 |
| Resistance Level | $8.40 | $2.59 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 9.45 | 96.97 |
Price Performance
Historical ComparisonAbout BSBK Bogota Financial Corp.
Bogota Financial Corp is a New Jersey-based bank. It offers personal and business banking services such as savings, certificates of deposits, online banking, loans, and many more. The Bank generally grants residential, commercial, and consumer loans to, and accepts deposits from customers in New Jersey.
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.